Identification

Name
Donepezil
Accession Number
DB00843  (APRD00039)
Type
Small Molecule
Groups
Approved
Description

Donepezil (Aricept), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome.

Structure
Thumb
Synonyms
  • Domepezil
  • Donepezil
  • Donepezilo
  • Donepezilum
External IDs
BNAG / E 2020
Product Ingredients
IngredientUNIICASInChI Key
Donepezil hydrochloride3O2T2PJ89D120011-70-3XWAIAVWHZJNZQQ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-donepezilTablet5 mgOralAccel Pharma Inc2014-09-04Not applicableCanada
Accel-donepezilTablet10 mgOralAccel Pharma Inc2014-09-04Not applicableCanada
Act DonepezilTablet5 mgOralActavis Pharma Company2013-12-27Not applicableCanada
Act DonepezilTablet10 mgOralActavis Pharma Company2013-12-27Not applicableCanada
Act Donepezil ODTTablet, orally disintegrating5 mgOralActavis Pharma Company2013-12-27Not applicableCanada
Act Donepezil ODTTablet, orally disintegrating10 mgOralActavis Pharma Company2013-12-27Not applicableCanada
Ag-donepezilTablet5 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-donepezilTablet10 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
AriceptTablet, film coated5 mg/1OralEisai Limited1996-11-25Not applicableUs
AriceptTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2008-05-09Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-donepezilTablet5 mgOralApotex Corporation2013-12-27Not applicableCanada
Apo-donepezilTablet10 mgOralApotex Corporation2014-12-27Not applicableCanada
DonepezilTablet10 mg/1OralA S Medication Solutions2015-02-022017-06-20Us
DonepezilTablet5 mg/1OralNucare Pharmaceuticals, Inc.2015-02-02Not applicableUs
DonepezilTablet5 mg/1OralAmerincan Health Packaging2017-02-01Not applicableUs
DonepezilTablet5 mg/1OralCamber Pharmaceuticals2015-02-02Not applicableUs
DonepezilTablet10 mg/1OralAmerincan Health Packaging2017-02-01Not applicableUs
DonepezilTablet5 mg/1OralNucare Pharmaceuticals, Inc.2015-02-02Not applicableUs
DonepezilTablet10 mg/1OralCamber Pharmaceuticals2015-02-02Not applicableUs
DonepezilTablet10 mg/1OralNucare Pharmaceuticals, Inc.2015-02-02Not applicableUs
International/Other Brands
Alzepil (Egis) / Davia (Terapia) / Depzil (Psyco Remedies) / Donecept (Actavis) / Donecil (ABL Pharma) / Donep (Alkem) / Donepex (Schafer) / Donesyn (Synthon) / Dopezil (Medis) / Eranz (Wyeth) / Memac (Pfizer) / Nomi-Nox (Johnson) / Pezale (Sandoz) / Redumas (Teva) / Zolpezil (Actavis)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Memantine and Donepezil Hydrochlorides Extended-releaseDonepezil hydrochloride (10 mg/1) + Memantine Hydrochloride (28 mg/1)Capsule, extended releaseOralAmneal Pharmaceuticals2017-02-01Not applicableUs
Memantine and Donepezil Hydrochlorides Extended-releaseDonepezil hydrochloride (10 mg/1) + Memantine Hydrochloride (14 mg/1)Capsule, extended releaseOralAmneal Pharmaceuticals2017-02-01Not applicableUs
NamzaricDonepezil hydrochloride (10 mg/1) + Memantine Hydrochloride (28 mg/1)CapsuleOralAllergan2014-12-24Not applicableUs
NamzaricDonepezil hydrochloride + Memantine HydrochlorideKitOralAllergan2016-11-28Not applicableUs
NamzaricDonepezil hydrochloride (10 mg/1) + Memantine Hydrochloride (7 mg/1)CapsuleOralAllergan2016-07-18Not applicableUs
NamzaricDonepezil hydrochloride (10 mg/1) + Memantine Hydrochloride (14 mg/1)CapsuleOralAllergan2014-12-24Not applicableUs
NamzaricDonepezil hydrochloride (10 mg/1) + Memantine Hydrochloride (21 mg/1)CapsuleOralAllergan2016-07-18Not applicableUs
Categories
UNII
8SSC91326P
CAS number
120014-06-4
Weight
Average: 379.492
Monoisotopic: 379.214743799
Chemical Formula
C24H29NO3
InChI Key
ADEBPBSSDYVVLD-UHFFFAOYSA-N
InChI
InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
IUPAC Name
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one
SMILES
COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1

Pharmacology

Indication

For the palliative treatment of mild to moderate dementia of the Alzheimer's type.

Structured Indications
Pharmacodynamics

Donepezil is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that donepezil alters the course of the underlying dementing process.

Mechanism of action

Donepezil is a piperidine derivative that is a centerally active, reversible inhibitor of acetylcholinesterase. This drug is structurally unrelated to other anticholinesterase agents. Donepezil's proposed mechanism of action involves the reversible inhibition of cholinesterases (eg. acetylcholinesterase), which prevents the hydrolysis of acetycholine, and leads to an increased concentration of acetylcholine at cholinergic synapses. Evidence suggests that the anticholinesterase activity of donepezil is relatively specific for acetylcholinesterase in the brain.

TargetActionsOrganism
AAcetylcholinesterase
inhibitor
Human
U5-hydroxytryptamine receptor 2A
other/unknown
Human
Absorption

Donepezil is well absorbed with a relative oral bioavailability of 100% and reaches peak plasma concentrations in 3 to 4 hours.

Volume of distribution
  • 12 L/kg
Protein binding

96%

Metabolism

Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 in the liver and also undergoes glucuronidation. The main metabolite, 6-O-desmethyl donepezil, has been reported to inhibit AChE to the same extent as donepezil in vitro.

Route of elimination

Donepezil is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified.

Half life

70 hours

Clearance
  • apparent plasma cl=0.13 L/hr/kg
Toxicity

Symptoms of overdose include severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*2A(G;G) / (C;G)C > GEffect Directly StudiedPatients with this genotype are have a decreased likelihood of responding to donepezil when treating Alzheimer's disease.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Donepezil.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Donepezil.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Donepezil.Experimental, Illicit
AbirateroneThe serum concentration of Donepezil can be increased when it is combined with Abiraterone.Approved
AcebutololDonepezil may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Donepezil is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Donepezil.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Donepezil.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Donepezil.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Donepezil.Experimental, Investigational
AlprenololDonepezil may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Donepezil.Approved
AmiodaroneThe metabolism of Donepezil can be decreased when combined with Amiodarone.Approved, Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Donepezil.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Donepezil.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Donepezil.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Donepezil.Approved
AprepitantThe serum concentration of Donepezil can be increased when it is combined with Aprepitant.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Donepezil is combined with Arecoline.Experimental
ArotinololDonepezil may increase the bradycardic activities of Arotinolol.Approved, Investigational
ArtemetherThe metabolism of Donepezil can be decreased when combined with Artemether.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Donepezil.Investigational
AtazanavirThe metabolism of Donepezil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololDonepezil may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe metabolism of Donepezil can be decreased when combined with Atomoxetine.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Donepezil.Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Donepezil.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Donepezil.Approved, Vet Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Donepezil.Approved, Investigational
BefunololDonepezil may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Donepezil.Withdrawn
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Donepezil.Approved
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Donepezil.Approved
BeractantDonepezil may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Donepezil.Approved, Vet Approved
BetaxololDonepezil may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Donepezil is combined with Bethanechol.Approved
BevantololDonepezil may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Donepezil.Approved, Investigational
BisoprololDonepezil may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe metabolism of Donepezil can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololDonepezil may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Donepezil.Experimental
BortezomibThe metabolism of Donepezil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Donepezil can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Donepezil.Approved
BucindololDonepezil may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Donepezil.Approved
BufuralolDonepezil may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololDonepezil may increase the bradycardic activities of Bupranolol.Approved
BupropionThe metabolism of Donepezil can be decreased when combined with Bupropion.Approved
CalfactantDonepezil may increase the bradycardic activities of Calfactant.Approved
CapecitabineThe metabolism of Donepezil can be decreased when combined with Capecitabine.Approved, Investigational
CarbacholThe risk or severity of adverse effects can be increased when Donepezil is combined with Carbachol.Approved
CarbamazepineThe metabolism of Donepezil can be increased when combined with Carbamazepine.Approved, Investigational
CarteololDonepezil may increase the bradycardic activities of Carteolol.Approved
CarvedilolDonepezil may increase the bradycardic activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Donepezil can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololDonepezil may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Donepezil can be increased when it is combined with Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Donepezil is combined with Cevimeline.Approved
ChloroquineThe metabolism of Donepezil can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Donepezil.Withdrawn
ChlorpromazineThe metabolism of Donepezil can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Donepezil can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Donepezil.Approved, Investigational
CimetidineThe metabolism of Donepezil can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Donepezil can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Donepezil can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Donepezil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Donepezil can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Donepezil can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Donepezil.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Donepezil.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Donepezil.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Donepezil.Approved
ClomipramineThe metabolism of Donepezil can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the bradycardic activities of Donepezil.Approved
CloranololDonepezil may increase the bradycardic activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Donepezil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Donepezil can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Donepezil can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Donepezil can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Donepezil can be increased when it is combined with Conivaptan.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Donepezil.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Donepezil.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Donepezil.Approved
CrisaboroleThe metabolism of Donepezil can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Donepezil can be decreased when combined with Crizotinib.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Donepezil.Approved
CyclosporineThe metabolism of Donepezil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Donepezil can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Donepezil.Approved, Investigational
DarunavirThe serum concentration of Donepezil can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Donepezil can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Donepezil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Donepezil can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Donepezil can be decreased when combined with Desipramine.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Donepezil.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Donepezil.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Donepezil.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Donepezil.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Donepezil.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Donepezil.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Donepezil.Withdrawn
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Donepezil.Approved, Vet Approved
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Donepezil.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Donepezil.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Donepezil.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Donepezil.Approved
DigoxinDigoxin may increase the bradycardic activities of Donepezil.Approved
DihydroergotamineThe metabolism of Donepezil can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Donepezil can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Donepezil can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe therapeutic efficacy of Donepezil can be decreased when used in combination with Dipyridamole.Approved
DosulepinThe metabolism of Donepezil can be decreased when combined with Dosulepin.Approved
DoxycyclineThe metabolism of Donepezil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Donepezil can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Donepezil can be decreased when combined with Duloxetine.Approved
EfavirenzThe metabolism of Donepezil can be decreased when combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Donepezil can be decreased when combined with Eliglustat.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Donepezil.Experimental
EnzalutamideThe serum concentration of Donepezil can be decreased when it is combined with Enzalutamide.Approved
EpanololDonepezil may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Donepezil is combined with Epibatidine.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Donepezil.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Donepezil.Approved
ErythromycinThe metabolism of Donepezil can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololDonepezil may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Donepezil.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Donepezil.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Donepezil.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Donepezil.Approved
EtravirineThe metabolism of Donepezil can be decreased when combined with Etravirine.Approved
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Donepezil.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Donepezil.Approved
FingolimodDonepezil may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloxuridineThe metabolism of Donepezil can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Donepezil.Investigational
FluconazoleThe metabolism of Donepezil can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Donepezil.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Donepezil.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Donepezil.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Donepezil.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Donepezil.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Donepezil.Approved
FluorouracilThe metabolism of Donepezil can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Donepezil can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Donepezil.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Donepezil.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Donepezil.Approved
FluvastatinThe metabolism of Donepezil can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Donepezil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Donepezil.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Donepezil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Donepezil can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Donepezil can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Donepezil can be increased when it is combined with Fusidic Acid.Approved
GalantamineGalantamine may increase the bradycardic activities of Donepezil.Approved
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Donepezil.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Donepezil.Approved
GemfibrozilThe metabolism of Donepezil can be decreased when combined with Gemfibrozil.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Donepezil.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Donepezil is combined with GTS-21.Investigational
GuanfacineDonepezil may increase the bradycardic activities of Guanfacine.Approved, Investigational
HaloperidolThe metabolism of Donepezil can be decreased when combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Donepezil.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Donepezil.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Donepezil.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Donepezil.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Donepezil.Approved
IdelalisibThe serum concentration of Donepezil can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Donepezil can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Donepezil can be decreased when combined with Imipramine.Approved
IndenololDonepezil may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Donepezil can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Donepezil.Approved
IrbesartanThe metabolism of Donepezil can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Donepezil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Donepezil can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Donepezil can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Donepezil.Investigational
ItraconazoleThe metabolism of Donepezil can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineDonepezil may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Donepezil can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Donepezil can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolDonepezil may increase the bradycardic activities of Labetalol.Approved
LacosamideDonepezil may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LandiololDonepezil may increase the bradycardic activities of Landiolol.Investigational
LanreotideDonepezil may increase the bradycardic activities of Lanreotide.Approved
LeflunomideThe metabolism of Donepezil can be decreased when combined with Leflunomide.Approved, Investigational
LevobunololDonepezil may increase the bradycardic activities of Levobunolol.Approved
LobeglitazoneThe metabolism of Donepezil can be decreased when combined with Lobeglitazone.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Donepezil is combined with Lobeline.Investigational
LopinavirThe metabolism of Donepezil can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Donepezil can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Donepezil can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Donepezil can be decreased when combined with Lovastatin.Approved, Investigational
LucinactantDonepezil may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Donepezil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Donepezil can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Donepezil can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Donepezil can be decreased when combined with Manidipine.Approved, Investigational
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Donepezil.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Donepezil.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Donepezil.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Donepezil.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Donepezil.Vet Approved
MepindololDonepezil may increase the bradycardic activities of Mepindolol.Experimental
MethacholineThe risk or severity of adverse effects can be increased when Donepezil is combined with Methacholine.Approved
MethadoneThe metabolism of Donepezil can be decreased when combined with Methadone.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Donepezil.Approved, Investigational
MethotrimeprazineThe metabolism of Donepezil can be decreased when combined with Methotrimeprazine.Approved
MethyldopaDonepezil may increase the bradycardic activities of Methyldopa.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Donepezil.Approved, Vet Approved
MetipranololDonepezil may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Donepezil.Approved
MetoprololDonepezil may increase the bradycardic activities of Metoprolol.Approved, Investigational
MidostaurinThe metabolism of Donepezil can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Donepezil can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Donepezil can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Donepezil can be decreased when it is combined with Mitotane.Approved
MivacuriumDonepezil may decrease the neuromuscular blocking activities of Mivacurium.Approved
NadololDonepezil may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Donepezil.Investigational
NebivololDonepezil may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Donepezil can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Donepezil can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Donepezil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Donepezil can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Donepezil can be decreased when combined with Nicardipine.Approved
NicotineThe risk or severity of adverse effects can be increased when Donepezil is combined with Nicotine.Approved
NilotinibThe metabolism of Donepezil can be decreased when combined with Nilotinib.Approved, Investigational
OctreotideOctreotide may increase the bradycardic activities of Donepezil.Approved, Investigational
OlaparibThe metabolism of Donepezil can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Donepezil.Investigational
OmeprazoleThe metabolism of Donepezil can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Donepezil.Approved
OsimertinibThe serum concentration of Donepezil can be increased when it is combined with Osimertinib.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Donepezil.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Donepezil.Investigational
OxprenololDonepezil may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Donepezil.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Donepezil.Approved
PalbociclibThe serum concentration of Donepezil can be increased when it is combined with Palbociclib.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Donepezil.Approved
PanobinostatThe serum concentration of Donepezil can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Donepezil.Approved
ParoxetineThe metabolism of Donepezil can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideDonepezil may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Donepezil can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololDonepezil may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Donepezil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Donepezil.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Donepezil.Experimental
PhenobarbitalThe metabolism of Donepezil can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Donepezil can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe risk or severity of adverse effects can be increased when Donepezil is combined with Pilocarpine.Approved
PindololDonepezil may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Donepezil.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Donepezil.Approved
Poractant alfaDonepezil may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Donepezil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDonepezil may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Donepezil.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Donepezil.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Donepezil.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Donepezil.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Donepezil.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Donepezil.Experimental, Investigational
PrimidoneThe metabolism of Donepezil can be increased when combined with Primidone.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Donepezil.Approved
PromazineThe metabolism of Donepezil can be decreased when combined with Promazine.Approved, Vet Approved
PropafenoneDonepezil may increase the bradycardic activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Donepezil.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Donepezil.Approved, Investigational
PropranololDonepezil may increase the bradycardic activities of Propranolol.Approved, Investigational
PyrimethamineThe metabolism of Donepezil can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinidineThe metabolism of Donepezil can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Donepezil can be decreased when combined with Quinine.Approved
RanolazineThe metabolism of Donepezil can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumDonepezil may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RifabutinThe metabolism of Donepezil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Donepezil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Donepezil can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Donepezil.Approved
RitonavirThe metabolism of Donepezil can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineDonepezil may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Donepezil can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Donepezil can be decreased when combined with Ropinirole.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Donepezil.Approved
SaquinavirThe metabolism of Donepezil can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Donepezil.Approved, Vet Approved
SecobarbitalThe metabolism of Donepezil can be increased when combined with Secobarbital.Approved, Vet Approved
SertralineThe metabolism of Donepezil can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Donepezil can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Donepezil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Donepezil can be increased when it is combined with Simeprevir.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Donepezil.Approved
SorafenibThe metabolism of Donepezil can be decreased when combined with Sorafenib.Approved, Investigational
SotalolDonepezil may increase the bradycardic activities of Sotalol.Approved
St. John's WortThe serum concentration of Donepezil can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Donepezil can be increased when it is combined with Stiripentol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Donepezil.Approved
SufentanilSufentanil may increase the bradycardic activities of Donepezil.Approved, Investigational
SulfadiazineThe metabolism of Donepezil can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Donepezil can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Donepezil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TalinololDonepezil may increase the bradycardic activities of Talinolol.Investigational
TelaprevirThe metabolism of Donepezil can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Donepezil can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Donepezil can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TertatololDonepezil may increase the bradycardic activities of Tertatolol.Experimental
ThioridazineThe metabolism of Donepezil can be decreased when combined with Thioridazine.Approved, Withdrawn
TicagrelorThe metabolism of Donepezil can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Donepezil can be decreased when combined with Ticlopidine.Approved
TimololDonepezil may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Donepezil.Approved
TipranavirThe metabolism of Donepezil can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Donepezil.Approved
TizanidineTizanidine may increase the bradycardic activities of Donepezil.Approved
TocilizumabThe serum concentration of Donepezil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Donepezil.Approved, Investigational
TolbutamideThe metabolism of Donepezil can be decreased when combined with Tolbutamide.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Donepezil.Approved, Investigational
TopiroxostatThe metabolism of Donepezil can be decreased when combined with Topiroxostat.Approved, Investigational
TranylcypromineThe metabolism of Donepezil can be decreased when combined with Tranylcypromine.Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Donepezil.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Donepezil.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Donepezil.Approved, Investigational
TrimethoprimThe metabolism of Donepezil can be decreased when combined with Trimethoprim.Approved, Vet Approved
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Donepezil.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Donepezil.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Donepezil.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Donepezil.Approved
Valproic AcidThe metabolism of Donepezil can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Donepezil can be decreased when combined with Valsartan.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Donepezil is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Donepezil.Approved
VenlafaxineThe metabolism of Donepezil can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Donepezil can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Donepezil can be decreased when combined with Voriconazole.Approved, Investigational
ZafirlukastThe metabolism of Donepezil can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Donepezil can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Akio Imai, Hideaki Watanabe, Takashi Kajima, Yasushi Ishihama, Akiyo Ohtsuka, Tomohide Tanaka, Yukio Narabu, "Polymorphs of donepezil hydrochloride and process for production." U.S. Patent US5985864, issued December, 1988.

US5985864
General References
  1. Xiong G, Doraiswamy PM: Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics. 2005 Jun;60(6):22-6. [PubMed:15948662]
  2. Yesavage JA, Mumenthaler MS, Taylor JL, Friedman L, O'Hara R, Sheikh J, Tinklenberg J, Whitehouse PJ: Donepezil and flight simulator performance: effects on retention of complex skills. Neurology. 2002 Jul 9;59(1):123-5. [PubMed:12105320]
  3. Sugimoto H: Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem Rec. 2001;1(1):63-73. [PubMed:11893059]
External Links
Human Metabolome Database
HMDB05041
KEGG Drug
D00670
PubChem Compound
3152
PubChem Substance
46504803
ChemSpider
3040
BindingDB
8960
ChEBI
53289
ChEMBL
CHEMBL502
Therapeutic Targets Database
DAP000560
PharmGKB
PA449394
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Donepezil
ATC Codes
N06DA02 — DonepezilN06DA53 — Donepezil, memantine and ginkgo foliumN06DA52 — Donepezil and memantine
AHFS Codes
  • 12:04.00 — Parasympathomemetic (Cholinergic) Agents
FDA label
Download (303 KB)
MSDS
Download (58.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAlzheimer's Disease (AD)1
0Unknown StatusBasic ScienceHealthy Volunteers1
1Active Not RecruitingTreatmentAlzheimer's Disease (AD)2
1Active Not RecruitingTreatmentDementia, Vascular / Memory Disturbances / Strokes1
1CompletedNot AvailableAdults / Healthy Volunteers1
1CompletedNot AvailableAlzheimer's Disease (AD)2
1CompletedNot AvailableCognitive Impairments1
1CompletedNot AvailableHealthy Adults2
1CompletedNot AvailableHealthy Volunteers9
1CompletedBasic ScienceCognition1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic SciencePain, Neuropathic1
1CompletedDiagnosticDementias1
1CompletedTreatmentAlzheimer's Disease (AD)4
1CompletedTreatmentAlzheimer's Disease (AD) / Battery1
1CompletedTreatmentAlzheimer's Disease (AD) / Central Nervous System Diseases1
1CompletedTreatmentAlzheimer's Disease (AD) / Memory Disturbances1
1CompletedTreatmentDementias1
1CompletedTreatmentFragile X Syndrome (FXS)1
1CompletedTreatmentHealthy Elderly Male1
1CompletedTreatmentHealthy Volunteers6
1Not Yet RecruitingTreatmentAlzheimer's Disease (AD)1
1RecruitingNot AvailableAlzheimer's Disease (AD)1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingTreatmentAlzheimer's Disease (AD)1
1RecruitingTreatmentAlzheimer's Disease (AD) / Healthy Volunteers1
1RecruitingTreatmentAmblyopia1
1TerminatedBasic ScienceAlzheimer's Disease (AD)1
1TerminatedTreatmentAlzheimer's Disease (AD) / Dementias1
1, 2CompletedNot AvailableAutism, Early Infantile / Cognition Disorder1
1, 2Unknown StatusHealth Services ResearchAlzheimer's Disease (AD)1
1, 2Unknown StatusTreatmentStroke, Acute1
2CompletedDiagnosticAlzheimer's Disease (AD)1
2CompletedPreventionDelirium1
2CompletedSupportive CareBrain and Central Nervous System Tumors / Radiation Toxicity1
2CompletedSupportive CareSmoking1
2CompletedTreatmentAlzheimer's Disease (AD)13
2CompletedTreatmentAnxiety Disorders / Cancer, Breast / Cognition Disorders / Depressive State / Sleep disorders and disturbances / Tiredness1
2CompletedTreatmentAutistic Disorder1
2CompletedTreatmentCocaine Abuse and Dependence1
2CompletedTreatmentCocaine Use Disorders1
2CompletedTreatmentCognitive Impairments1
2CompletedTreatmentDementia Alzheimer's Type1
2CompletedTreatmentDementia With Lewy Bodies (DLB)2
2CompletedTreatmentDown Syndrome (DS)1
2CompletedTreatmentFragile X Syndrome (FXS)1
2CompletedTreatmentIrritation/Irritant1
2CompletedTreatmentMigrainous Headache1
2CompletedTreatmentPost-traumatic Neuropathic Pain1
2CompletedTreatmentStroke, Ischemic1
2Not Yet RecruitingTreatmentAlzheimer's Disease (AD)1
2Not Yet RecruitingTreatmentParkinson's Disease (PD)1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders1
2RecruitingTreatmentCognitive Impairments1
2RecruitingTreatmentMild-Moderate Alzheimer's Disease1
2RecruitingTreatmentParkinson's Disease (PD)3
2TerminatedBasic ScienceAlzheimer's Disease (AD)1
2TerminatedTreatmentAlzheimer's Disease (AD)3
2TerminatedTreatmentAneurysmal Subarachnoid Hemorrhage / Delayed Cerebral Ischemia / Delayed Neurological Deficit / Vasospasm1
2TerminatedTreatmentAutism Spectrum Conditions/Disorders1
2TerminatedTreatmentDown Syndrome (DS)1
2TerminatedTreatmentSchizophrenic Disorders1
2Unknown StatusTreatmentAlzheimer's Disease (AD) / Memory Disorders1
2Unknown StatusTreatmentSupranuclear Palsy, Progressive1
2, 3RecruitingTreatmentAlzheimer's1
3Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
3CompletedSupportive CareBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Metastatic Cancers / Psychosocial Effects of Cancer and Its Treatment / Radiation Toxicity / Tiredness1
3CompletedSupportive CareCognitive/Functional Effects / Delirium / Depressive State / Lung Cancers / Radiation Toxicity1
3CompletedTreatmentAlzheimer's Disease (AD)4
3CompletedTreatmentAlzheimer's Disease (AD) / Dementias2
3CompletedTreatmentAttention Impairment1
3CompletedTreatmentDementia Associated With Cerebrovascular Disease1
3CompletedTreatmentDementia With Lewy Bodies (DLB)1
3CompletedTreatmentDementia With Parkinson's Disease1
3CompletedTreatmentDementia, Alzheimer Type1
3CompletedTreatmentDementia, Vascular1
3CompletedTreatmentMild Cognitive Impairment (MCI)1
3Not Yet RecruitingPreventionFemoral Head Necrosis / Rheumatoid Arthritis / Synovitis of osteoarthritis1
3Not Yet RecruitingTreatmentAlzheimer's Disease (AD)1
3RecruitingTreatmentAlzheimer's Disease (AD)1
3RecruitingTreatmentCognitive Dysfunctions / Memory Disturbances1
3RecruitingTreatmentDementia, Vascular1
3RecruitingTreatmentMemory Disturbances / Traumatic Brain Injury (TBI)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentCancer, Advanced1
3TerminatedTreatmentCognitive Dysfunctions / Down Syndrome (DS)1
3TerminatedTreatmentDementia, Mixed / Dementia, Vascular1
3TerminatedTreatmentDown Syndrome, Cognitive Dysfunction1
3TerminatedTreatmentParkinson's Disease (PD)1
3Unknown StatusTreatmentDementia of Alzheimer's Type1
3Unknown StatusTreatmentRett's Syndrome1
3Unknown StatusTreatmentStroke, Ischemic1
3WithdrawnTreatmentDisseminated Sclerosis1
4Active Not RecruitingOtherAlzheimer's Disease (AD)1
4Active Not RecruitingTreatmentPain, Neuropathic1
4CompletedBasic ScienceSleep Deprivation1
4CompletedPreventionCognition Disorders1
4CompletedPreventionCognitively Normal Elderly Individuals1
4CompletedPreventionDelirium / Postoperative Complications2
4CompletedSupportive CareGeriatrics / Mental Health1
4CompletedTreatmentAlzheimer's Disease (AD)6
4CompletedTreatmentAlzheimer's Disease (AD) / Cognition Disorders1
4CompletedTreatmentAlzheimer's Disease (AD) / Sleep Apnea, Obstructive1
4CompletedTreatmentAphasia / Strokes1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentCerebrovascular Accidents1
4CompletedTreatmentDementia, Alzheimer Type1
4CompletedTreatmentDementia, Vascular1
4CompletedTreatmentDementias1
4CompletedTreatmentDementias / Depressive State1
4CompletedTreatmentDepressive State / Mild Cognitive Impairment (MCI)1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentMemory1
4CompletedTreatmentMemory Losses1
4CompletedTreatmentMild Cognitive Impairment (MCI)2
4CompletedTreatmentMild to Severe Alzheimer's Disease1
4CompletedTreatmentObstructive Sleep Apnea (OSA)1
4CompletedTreatmentParkinson's Disease (PD)1
4Not Yet RecruitingTreatmentAlzheimer's Disease (AD) / Cognitive Function1
4Not Yet RecruitingTreatmentParkinson's Disease (PD)1
4RecruitingBasic ScienceAmblyopia1
4RecruitingOtherGenetic Risk for Alzheimer's Disease1
4RecruitingPreventionAlzheimer's Disease (AD) / Delirium, Dementia, Amnestic, Cognitive Disorders / Mild Cognitive Impairment (MCI)1
4RecruitingTreatmentAlzheimer's Disease (AD)1
4RecruitingTreatmentDementia Associated With Cerebrovascular Disease1
4TerminatedTreatmentAlzheimer's Disease (AD)2
4TerminatedTreatmentChronic Low Back Pain (CLBP) / Diabetic Neuropathic Pain1
4TerminatedTreatmentDelirium of Unknown (Axis III) Etiology / Elderly / Intensive Care (ICU) Myopathy1
4Unknown StatusPreventionAlzheimer's Disease (AD)1
4Unknown StatusTreatmentAlzheimer's Disease (AD) / Dementias1
4Unknown StatusTreatmentImpaired Cognition / Schizophrenic Disorders1
4Unknown StatusTreatmentModerate to Severe Alzheimer's Disease1
4Unknown StatusTreatmentObstructive Sleep Apnea (OSA)1
4Unknown StatusTreatmentParkinson's Disease (PD)1
4Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4WithdrawnTreatmentAlzheimer's Disease (AD)1
4WithdrawnTreatmentSevere Alzheimer's Disease1
Not AvailableActive Not RecruitingNot AvailableDementia With Lewy Body Disease1
Not AvailableActive Not RecruitingPreventionBalance / Falls / Gait / Mild Cognitive Impairment (MCI)1
Not AvailableActive Not RecruitingSupportive CareBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Children / Neurotoxicity / Psychosocial Effects of Cancer and Its Treatment / Radiation Toxicity1
Not AvailableCompletedNot AvailableAlzheimer's Desease1
Not AvailableCompletedNot AvailableAlzheimer's Disease (AD)4
Not AvailableCompletedNot AvailableAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedNot AvailableBiomarkers, Pharmacological1
Not AvailableCompletedNot AvailableCholinergic Function1
Not AvailableCompletedNot AvailableDiffuse Lewy Body Disease1
Not AvailableCompletedPreventionElderly1
Not AvailableCompletedSupportive CareDementia With Lewy Bodies (DLB)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD) / Caregivers1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD) / Dementias2
Not AvailableCompletedTreatmentMemory Disorders1
Not AvailableCompletedTreatmentModerate Alzheimer's Disease1
Not AvailableCompletedTreatmentParkinson's Disease (PD)1
Not AvailableCompletedTreatmentRett's Syndrome1
Not AvailableRecruitingNot AvailableAlzheimer's Disease (AD)1
Not AvailableRecruitingPreventionMemory Disturbances1
Not AvailableTerminatedBasic ScienceAlzheimer's Disease (AD)1
Not AvailableTerminatedTreatmentAlzheimer's Disease (AD) / Dementias1
Not AvailableUnknown StatusNot AvailableStrokes1

Pharmacoeconomics

Manufacturers
  • Eisai inc
  • Mutual pharmaceutical co inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral5 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral5 mg
TabletOral10 mg/1
TabletOral23 mg/1
TabletOral5 mg/1
Tablet, extended releaseOral23 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral23 mg/1
Tablet, film coatedOral5 mg/1
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral5 mg/1
Capsule, extended releaseOral
CapsuleOral
KitOral
Prices
Unit descriptionCostUnit
Aricept ODT 30 5 mg Dispersible Tablet Box272.99USD box
Aricept 10 mg tablet10.93USD tablet
Aricept 5 mg tablet9.78USD tablet
Aricept odt 10 mg tablet8.03USD tablet
Aricept odt 5 mg tablet8.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4895841No1993-11-252010-11-25Us
CA2252806No2005-11-222017-06-06Canada
CA1338808No1996-12-242013-12-24Canada
US7727548No2002-06-232022-06-23Us
US7727552No1998-03-262018-03-26Us
US8173708Yes2006-05-222026-05-22Us
US8283379Yes2006-05-222026-05-22Us
US8362085Yes2006-05-222026-05-22Us
US8039009Yes2009-09-242029-09-24Us
US8329752Yes2006-05-222026-05-22Us
US8598233Yes2006-05-222026-05-22Us
US8168209Yes2006-05-222026-05-22Us
US8481565No2006-10-042026-10-04Us
US8338486No2005-11-222025-11-22Us
US8058291No2009-12-052029-12-05Us
US8580858No2005-11-222025-11-22Us
US8338485No2005-11-222025-11-22Us
US8293794No2005-11-222025-11-22Us
US5061703Yes1995-10-112015-10-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)206.72 °CNot Available
water solubility2.931 mg/LNot Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP4.14ALOGPS
logP4.21ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)17.02ChemAxon
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity112.11 m3·mol-1ChemAxon
Polarizability44.34 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9953
Caco-2 permeable+0.7742
P-glycoprotein substrateSubstrate0.7721
P-glycoprotein inhibitor IInhibitor0.7641
P-glycoprotein inhibitor IIInhibitor0.8202
Renal organic cation transporterInhibitor0.7696
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7202
CYP450 1A2 substrateInhibitor0.5072
CYP450 2C9 inhibitorNon-inhibitor0.8189
CYP450 2D6 inhibitorInhibitor0.8684
CYP450 2C19 inhibitorNon-inhibitor0.8356
CYP450 3A4 inhibitorNon-inhibitor0.7411
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6138
Ames testNon AMES toxic0.6441
CarcinogenicityNon-carcinogens0.9528
BiodegradationNot ready biodegradable0.9145
Rat acute toxicity3.0123 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5386
hERG inhibition (predictor II)Inhibitor0.8095
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Indanones / Phenylmethylamines / Benzylamines / Aryl alkyl ketones / Anisoles / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 2 more
Substituents
N-benzylpiperidine / Indanone / Indane / Anisole / Benzylamine / Phenylmethylamine / Aryl ketone / Aryl alkyl ketone / Alkyl aryl ether / Aralkylamine
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
piperidines, cyclic ketone (CHEBI:53289)

Targets

Details
1. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Davis KL: Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington. Geriatrics. 1999 Feb;54(2):42-7; quiz 48. [PubMed:10024872]
  2. Kryger G, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure. 1999 Mar 15;7(3):297-307. [PubMed:10368299]
  3. Shepherd G, Klein-Schwartz W, Edwards R: Donepezil overdose: a tenfold dosing error. Ann Pharmacother. 1999 Jul-Aug;33(7-8):812-5. [PubMed:10466911]
  4. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y: Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol. 1999 Sep 10;380(2-3):101-7. [PubMed:10513568]
  5. Jann MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy. 2000 Jan;20(1):1-12. [PubMed:10641971]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Sugimoto H: Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem Rec. 2001;1(1):63-73. [PubMed:11893059]
  8. Ki YS, Park EY, Lee HW, Oh MS, Cho YW, Kwon YK, Moon JH, Lee KT: Donepezil, a potent acetylcholinesterase inhibitor, induces caspase-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull. 2010;33(6):1054-9. [PubMed:20522977]
  9. Repantis D, Laisney O, Heuser I: Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010 Jun;61(6):473-81. doi: 10.1016/j.phrs.2010.02.009. Epub 2010 Mar 1. [PubMed:20193764]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Hayslett RL, Tizabi Y: Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome. Pharmacol Biochem Behav. 2005 Aug;81(4):879-86. [PubMed:16045972]
  2. Hayslett RL, Tizabi Y: Effects of donepezil on DOI-induced head twitch response in mice: implications for Tourette syndrome. Pharmacol Biochem Behav. 2003 Dec;76(3-4):409-15. [PubMed:14643839]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49